{"id":"d46c4a9b-cf87-57b1-b934-036871c7ff0e","stable_key":"44eaeae5-557a-552b-8998-884f30462e2a:sulforaphane-autism-abc-early","predicate":"reduced","statement":"The active group showed a 34% ABC-score reduction at 18 weeks, with a significant between-treatment comparison.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"557a9f90-eb8c-5783-b4d9-1510b605b6fc","mechanism_event_label":"One early trial reported improvement in this symptom scale.","subject":{"id":"67e70215-70c4-546a-84b4-0819fac0b326","slug":"sulforaphane","display_name":"Sulforaphane / SFN, stereochemistry specified per study","entity_type_key":"small_molecule"},"object":{"id":"57835bb6-4a24-58d9-a078-cc228123f546","slug":"autism-abc-score","display_name":"Aberrant Behavior Checklist score, population specified","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"557a9f90-eb8c-5783-b4d9-1510b605b6fc","stable_key":"44eaeae5-557a-552b-8998-884f30462e2a:sulforaphane-autism-abc-early-event","event_type":"biochemical_relationship","label":"One early trial reported improvement in this symptom scale.","description":"The active group showed a 34% ABC-score reduction at 18 weeks, with a significant between-treatment comparison.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"67e70215-70c4-546a-84b4-0819fac0b326","slug":"sulforaphane","display_name":"Sulforaphane / SFN, stereochemistry specified per study","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"57835bb6-4a24-58d9-a078-cc228123f546","slug":"autism-abc-score","display_name":"Aberrant Behavior Checklist score, population specified","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/sulforaphane-research/25313065.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"d6f39bcdb3d5d89fd9226e208c82da13d9f18fee2003a8c817c67da0e344fd44\", \"start_char\": 0, \"end_char\": 1872, \"text_sha256\": \"d6f39bcdb3d5d89fd9226e208c82da13d9f18fee2003a8c817c67da0e344fd44\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized double-blind placebo-controlled trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Sulforaphane 50-150 micromol/day for 18 weeks, then four weeks off","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small male-only study; symptom-scale changes are not a cure and do not establish mechanism.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Sulforaphane research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"sulforaphane","display_name":"Sulforaphane / SFN, stereochemistry specified per study","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human, 44 males aged 13-27, 29 active and 15 placebo","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"One early trial reported improvement in this symptom scale.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[sulforaphane-p25313065] Sulforaphane treatment of autism spectrum disorder (ASD). (2014). https://pubmed.ncbi.nlm.nih.gov/25313065/ DOI: 10.1073/pnas.1416940111","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"ABC and SRS behavioral ratings","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"8cced5d1-f1f5-5642-aa36-3bdc3077dfc6","evidence_kind":"source_excerpt","locator":"Lines 1334-1345","start_line":1334,"end_line":1345,"excerpt":"### sulforaphane-autism-abc-early\nThe active group showed a 34% ABC-score reduction at 18 weeks, with a significant between-treatment comparison.\nCondition category: normal\nnutrient_topic: Sulforaphane research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: One early trial reported improvement in this symptom scale.\norganism: Human, 44 males aged 13-27, 29 active and 15 placebo\ntissue_or_cell_type: ABC and SRS behavioral ratings\nexperimental_model: Randomized double-blind placebo-controlled trial\nlimitations: Small male-only study; symptom-scale changes are not a cure and do not establish mechanism.\nexposure: Sulforaphane 50-150 micromol/day for 18 weeks, then four weeks off\nevidence_span: {\"source_cache\": \"artifacts/sulforaphane-research/25313065.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"d6f39bcdb3d5d89fd9226e208c82da13d9f18fee2003a8c817c67da0e344fd44\", \"start_char\": 0, \"end_char\": 1872, \"text_sha256\": \"d6f39bcdb3d5d89fd9226e208c82da13d9f18fee2003a8c817c67da0e344fd44\"}\n[sulforaphane-p25313065] Sulforaphane treatment of autism spectrum disorder (ASD). (2014). https://pubmed.ncbi.nlm.nih.gov/25313065/ DOI: 10.1073/pnas.1416940111","model_system":"Randomized double-blind placebo-controlled trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [sulforaphane-p25313065] Sulforaphane treatment of autism spectrum disorder (ASD). (2014). https://pubmed.ncbi.nlm.nih.gov/25313065/ DOI: 10.1073/pnas.1416940111","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a4bafbf7-f117-53c9-a6d7-8fb25e4aca72","stable_key":"import-44eaeae5-557a-552b-8998-884f30462e2a","title":"Sulforaphane: formation, electrophile sensing and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"f355c492a6c35673d8260b1328667fe206e5315b9fcaa5aeff53d80373c7ef97","revision_id":"f2c47d71-34cd-5160-8e92-fe196b576707","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}